234 related articles for article (PubMed ID: 30997872)
1. Vision loss with pembrolizumab treatment: A report of two cases.
Telfah M; Whittaker TJ; C Doolittle G
J Oncol Pharm Pract; 2019 Sep; 25(6):1540-1546. PubMed ID: 30997872
[TBL] [Abstract][Full Text] [Related]
2. Case report: Bilateral uveitis and papillitis secondary to treatment with pembrolizumab.
Navarro-Perea C; Garcia-Gonzalez J; Perez-Blazquez E
Indian J Ophthalmol; 2019 Dec; 67(12):2075-2077. PubMed ID: 31755465
[TBL] [Abstract][Full Text] [Related]
3. PEMBROLIZUMAB ADMINISTRATION ASSOCIATED WITH POSTERIOR UVEITIS.
Aaberg MT; Aaberg TM
Retin Cases Brief Rep; 2017 Fall; 11(4):348-351. PubMed ID: 27490976
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab-related Bilateral Ocular Hypotony, Uveitis, Cataracts, Exudative Retinal, and Choroidal Detachments: An Unusual Success Story.
Golash V; Almeida G
J Immunother; 2020; 43(9):283-285. PubMed ID: 32740318
[TBL] [Abstract][Full Text] [Related]
5. BILATERAL CHOROIDAL DETACHMENTS SECONDARY TO IPILIMUMAB AND PEMBROLIZUMAB USE.
O'Bryhim BE; Sychev Y; Rao PK
Retin Cases Brief Rep; 2021 May; 15(3):230-233. PubMed ID: 30044269
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab-related systemic myositis involving ocular and hindneck muscles resembling myasthenic gravis: a case report.
Kamo H; Hatano T; Kanai K; Aoki N; Kamiyama D; Yokoyama K; Takanashi M; Yamashita Y; Shimo Y; Hattori N
BMC Neurol; 2019 Aug; 19(1):184. PubMed ID: 31382909
[TBL] [Abstract][Full Text] [Related]
7. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
Hanna KS
Pharmacotherapy; 2016 Nov; 36(11):e183-e188. PubMed ID: 27716999
[TBL] [Abstract][Full Text] [Related]
8. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
9. Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy.
Quach HT; Robbins CJ; Balko JM; Chiu CY; Miller S; Wilson MR; Nelson GE; Johnson DB
Oncologist; 2019 Jul; 24(7):872-876. PubMed ID: 30936376
[TBL] [Abstract][Full Text] [Related]
10. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
[TBL] [Abstract][Full Text] [Related]
11. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
Li D; He C; Xia Y; Du Y; Zhang J
J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
[TBL] [Abstract][Full Text] [Related]
13. Behcet's-like syndrome following pembrolizumab: An immune-related adverse event associated with programmed death receptor-1 inhibitor therapy.
Thomas S; Bae C; Joy-Ann T; Traverse W
J Oncol Pharm Pract; 2020 Jun; 26(4):995-999. PubMed ID: 31575354
[TBL] [Abstract][Full Text] [Related]
14. Isolated optic neuritis after pembrolizumab administration for non-small-cell lung carcinoma.
Makri OE; Dimitrakopoulos FI; Tsapardoni F; Tsekouras I; Argyriou AA; Kalofonos H; Georgakopoulos CD
Int J Neurosci; 2022 Jul; 132(7):643-648. PubMed ID: 32998608
[TBL] [Abstract][Full Text] [Related]
15. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
[TBL] [Abstract][Full Text] [Related]
17. Management of Chronic Hypotony Following Bilateral Uveitis in a Patient Treated with Pembrolizumab for Cutaneous Metastatic Melanoma.
Reid G; Lorigan P; Heimann H; Hovan M
Ocul Immunol Inflamm; 2019; 27(6):1012-1015. PubMed ID: 29672247
[No Abstract] [Full Text] [Related]
18. BILATERAL SEROUS RETINAL DETACHMENT AND UVEITIS ASSOCIATED WITH PEMBROLIZUMAB TREATMENT IN METASTATIC MELANOMA.
de Vries EW; Schauwvlieghe AS; Haanen JB; de Hoog J
Retin Cases Brief Rep; 2022 Jul; 16(4):430-434. PubMed ID: 32243282
[TBL] [Abstract][Full Text] [Related]
19. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab.
Abu Samra K; Valdes-Navarro M; Lee S; Swan R; Foster CS; Anesi SD
Eur J Ophthalmol; 2016 Apr; 26(3):e46-8. PubMed ID: 26692064
[TBL] [Abstract][Full Text] [Related]
20. Motor polyradiculopathy during pembrolizumab treatment of metastatic melanoma.
Sepúlveda M; Martinez-Hernandez E; Gaba L; Victoria I; Sola-Valls N; Falgàs N; Casanova-Molla J; Graus F
Muscle Nerve; 2017 Dec; 56(6):E162-E167. PubMed ID: 28439919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
